2. Academic Validation
  3. CX26 promotes pancreatic cancer progression by competitively inhibiting interaction of c-Myc with PSMD2 and enhancing c-Myc stability

CX26 promotes pancreatic cancer progression by competitively inhibiting interaction of c-Myc with PSMD2 and enhancing c-Myc stability

  • J Transl Med. 2025 Aug 19;23(1):939. doi: 10.1186/s12967-025-06983-5.
Cheng He # 1 2 3 4,  Chuanyu Tang # 1 2 3 4,  Jie Guo 1 2 3 4,  Xiangyi Yin 1 2 3 4,  Qing Zhu 1 2 3 4,  Chihua Fang 5 6 7 8
Affiliations

Affiliations

  • 1 Department of Hepatobiliary Surgery I, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China.
  • 2 Guangdong Provincial Clinical and Engineering Center of Digital Medicine, Guangzhou, 510280, China.
  • 3 National Engineering Research Center of Innovation and Application of Minimally Invasive Instruments - South China Institute, Guangzhou, 510280, China.
  • 4 Digital Intelligent Minimally Invasive Surgery Institute, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China.
  • 5 Department of Hepatobiliary Surgery I, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China. fangchihua@smu.edu.cn.
  • 6 Guangdong Provincial Clinical and Engineering Center of Digital Medicine, Guangzhou, 510280, China. fangchihua@smu.edu.cn.
  • 7 National Engineering Research Center of Innovation and Application of Minimally Invasive Instruments - South China Institute, Guangzhou, 510280, China. fangchihua@smu.edu.cn.
  • 8 Digital Intelligent Minimally Invasive Surgery Institute, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China. fangchihua@smu.edu.cn.
  • # Contributed equally.
PMID: 40830962 DOI: 10.1186/s12967-025-06983-5
Abstract

Background: Pancreatic Cancer (PC) is highly aggressive and fatal and has dismal prognostic outcomes, primarily due to its late-stage diagnosis and limited effective treatments. The molecular mechanisms triggering PC progression are largely unclear. This study investigated how CX26 contributes to pancreatic Cancer development and its potential as a therapeutic target.

Methods: CX26 expression in PC and its clinical significance were examined through bioinformatics analysis. The biological functions of CX26 in PC cells were explored via colony formation, CCK-8, and proteomic analysis. To explore the mechanisms by which CX26 regulates c-Myc stability, co-immunoprecipitation, immunofluorescence, and molecular docking were utilized to investigate the interactions among CX26, PSMD2, and c-Myc. Additionally, subcutaneous xenografts in nude mice were applied to assess the impact of CX26 on PC progression in vivo.

Results: Bioinformatics analysis indicated the upregulation of CX26 in PC tissues. In addition, CX26 expression was closely related to dismal prognostic outcomes. Further study revealed that CX26 promotes PC progression in vitro and in vivo. Proteomic analysis identified c-Myc as the key downstream target of CX26. Mechanistically, CX26 indirectly regulated c-Myc stability via PSMD2 rather than directly interacting with c-Myc. Moreover, CX26 competes with c-Myc to bind to the Armadillo-like helical domain of PSMD2, thereby preventing c-Myc proteasomal degradation.

Conclusions: This study suggests that CX26 facilitates PC progression by stabilizing c-Myc through competitively inhibiting the binding of PSMD2 to c-Myc. Given the challenges in directly inhibiting c-Myc, this novel regulatory mechanism provides valuable insights into PC biology and reveals that targeting CX26 is a possible way to promote c-Myc degradation and suppress PC growth.

Keywords

CX26; PSMD2; Pancreatic cancer; Proteasomal degradation; c-Myc.

Figures
Products